StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 8.8
Power Rank trend -> Rising
07/26/2024 16:00:00 EST
Novocure Ltd (NVCR)
Industry: Medical Devices
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, NVCR has been trading in a range between $19.28 and $16.00 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
The AI powered stock chart is in a Yellow zone which means the stock is transitioning zones. We would avoid this stock currently.
Upside / Downside Potential
Novocure Ltd $NVCR entered a Yellow zone 3 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $56.57, a potential upside of 197.42% from the recent price of 19.02. The stock is trading 84.54% (potential upside) below its 52 week high of $35.10 and 74.98 % (potential downside) above its 52 week low of $10.87 - based on the recent price.
Company Summary
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
News
| NovoCure Limited: A Post Q2 Analysis Today, we take a look at NovoCure Limited, which develops and manufactures tumor treating fields devices for solid tumor cancers. The company has beat expectations for both its first and second quarter results in 2024 and is pushing to garner approval for additional indications. An analysis of NovoCure following its better than expected performance Q2 results Thursday follows in the paragraphs below. Source: Seeking Alpha Fri, 26 Jul 2024 12:34:32 -0400 Sentiment: Positive |
| NovoCure's Q2 Revenue Soars by 10.7% Its loss of $0.31 per share was smaller than the expected loss of $0.40 per share. Total net revenues of $150.4 million surpassed Wall Street's estimate of $135.8 million by 10.7%. Source: The Motley Fool Fri, 26 Jul 2024 11:42:24 -0400 Sentiment: Positive |
| NovoCure Limited (NVCR) Q2 2024 Earnings Call Transcript NovoCure Limited [NVCR] Q2 2024 Earnings Conference Call July 25, 2024 8:00 AM ET Company Participants Bill Doyle - Executive Chairman Asaf Danziger - CEO Ashley Cordova - CFO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Ingrid Goldberg - Investor Relations Conference Call Participants Jonathan Chang - Leerink Partners Jason Bednar - Piper Sandler Larry Biegelsen - Wells Fargo Jessica Fye - J.P. Morgan Vijay Kumar - Evercore ISI Emily Bodnar - H.C. Source: Seeking Alpha Thu, 25 Jul 2024 12:35:09 -0400 Sentiment: Neutral |
| NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.54 per share a year ago. Source: Zacks Investment Research Thu, 25 Jul 2024 09:10:43 -0400 Sentiment: Negative |
| Novocure Reports Second Quarter 2024 Financial Results ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2024. Source: Business Wire Thu, 25 Jul 2024 07:00:00 -0400 Sentiment: Neutral |
Technicals 52 Week Hi: 35.1 52 Week Low: 10.87 Beta: 0.694 50 Day MA: 19.9769 200 Day MA: 15.4782 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.06 Qtr Revenue Growth YOY: 0.193 Forward PE: 909.0909 Trailing PE: 0